Matches in DBpedia 2015-04 for { <http://dbpedia.org/resource/Vatalanib> ?p ?o }
Showing triples 1 to 63 of
63
with 100 triples per page.
- Vatalanib abstract "Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth.Vatalanib is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2.".
- Vatalanib atcPrefix "none".
- Vatalanib casNumber "212141-54-3".
- Vatalanib fdaUniiCode "5DX9U76296".
- Vatalanib iupacName "N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin- 1-amine".
- Vatalanib pubchem "151194".
- Vatalanib thumbnail Vatalanib.svg?width=300.
- Vatalanib wikiPageExternalLink results?intr=%22Vatalanib%22.
- Vatalanib wikiPageID "20341296".
- Vatalanib wikiPageRevisionID "593274828".
- Vatalanib atcPrefix "none".
- Vatalanib bioavailability "High".
- Vatalanib c "20".
- Vatalanib casNumber "212141".
- Vatalanib chembl "101253".
- Vatalanib chemspiderid "133257".
- Vatalanib cl "1".
- Vatalanib eliminationHalfLife "3960.0".
- Vatalanib excretion "Fecal and renal".
- Vatalanib h "15".
- Vatalanib hasPhotoCollection Vatalanib.
- Vatalanib iupacName "N--4-phthalazin- 1-amine".
- Vatalanib legalStatus "Investigational".
- Vatalanib metabolism "Extensive hepatic metabolism".
- Vatalanib molecularWeight "346.813".
- Vatalanib n "4".
- Vatalanib pregnancyCategory "None assigned".
- Vatalanib pubchem "151194".
- Vatalanib routesOfAdministration "Oral".
- Vatalanib smiles "Clc1cccNc3nncCc4ccncc4".
- Vatalanib unii "5".
- Vatalanib width "180".
- Vatalanib subject Category:Angiogenesis_inhibitors.
- Vatalanib subject Category:Experimental_cancer_drugs.
- Vatalanib subject Category:Tyrosine_kinase_inhibitors.
- Vatalanib type Agent114778436.
- Vatalanib type AngiogenesisInhibitor102711422.
- Vatalanib type AngiogenesisInhibitors.
- Vatalanib type Antineoplastic102722458.
- Vatalanib type CausalAgent100007347.
- Vatalanib type CytotoxicDrug103157987.
- Vatalanib type Drug103247620.
- Vatalanib type ExperimentalCancerDrugs.
- Vatalanib type Matter100020827.
- Vatalanib type Medicine103740161.
- Vatalanib type PhysicalEntity100001930.
- Vatalanib type Substance100020090.
- Vatalanib type TyrosineKinaseInhibitor104506005.
- Vatalanib type TyrosineKinaseInhibitors.
- Vatalanib type Drug.
- Vatalanib type DrugProduct.
- Vatalanib type Thing.
- Vatalanib type Q8386.
- Vatalanib comment "Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth.Vatalanib is being developed by Bayer Schering and Novartis.".
- Vatalanib label "Vatalanib".
- Vatalanib differentFrom Vandetanib.
- Vatalanib sameAs m.04zzj85.
- Vatalanib sameAs Q7917084.
- Vatalanib sameAs Q7917084.
- Vatalanib sameAs Vatalanib.
- Vatalanib wasDerivedFrom Vatalanib?oldid=593274828.
- Vatalanib depiction Vatalanib.svg.
- Vatalanib isPrimaryTopicOf Vatalanib.
